Antibody-drug conjugates

Antibody-drug conjugates (ADCs) are a new type of targeted therapy, used for example for cancer

Antibody-drug conjugates (ADCs) are a new type of targeted therapy, used for example for cancer.They consist of an antibody (or antibody fragment such as a single-chain variable fragment [scFv]) linked to a payload drug (often cytotoxic). Hence, they are a type of immunoconjugate and often an immunotoxin.

See report: Antibody Partnering Terms and Agreements

Antibody-drug conjugates (ADCs) are a new type of targeted therapy, used for example for cancer.

They consist of an antibody (or antibody fragment such as a single-chain variable fragment [scFv]) linked to a payload drug (often cytotoxic). Hence, they are a type of immunoconjugate and often an immunotoxin.

The antibody causes the ADC to bind to the target cancer cells. Often the ADC is then internalized by the cell and the drug is released to do its damage. Because of the targeting, the side effects should be lower and give a wider therapeutic window.

Hydrophilic linkers (e.g., PEG4Mal) help prevent the drug being pumped out of resistant cancer cells through MDR (multiple drug resistance) transporters.

ADCs based on cleavable linkers are thought to have a less favorable therapeutic window, but targets (tumor cell surface antigens) that do not get internalized efficiently seem more suitable for cleavable linkers.

See report: Antibody Partnering Terms and Agreements

Example deal is as follows:

Collaboration agreement for novel antibody drug conjugates

Astellas, Ambrx - April 2013

Astellas Pharma entered into a collaboration with Ambrx  for the discovery and development of novel antibody drug conjugates.

ADCs allow for the targeted delivery of drugs to the target tissue.

Ambrx creates optimized ADCs using its site-specific conjugation technology along with proprietary linkers and payloads.

Ambrx will receive an upfront payment of $15 million from Astellas, as well as up to $285 million in potential near and long-term research, development, regulatory and sales-based milestones for an undisclosed number of targets for ADCs in oncology.

A portion of these milestones, as well as royalties on any net sales, will be contingent on eventual successful commercialization of products developed as a result of this partnership.

Astellas will receive worldwide rights to develop and commercialize ADCs for oncology.

Additional terms of the collaboration are not disclosed at this time.

Read the full deal at Current Agreements (subscription required)

View our report title: Antibody Partnering Terms and Agreements

Antibody definition

Monoclonal antibodies

Polyclonal antibodies

Read: more on antibody deals in pharma, biotech, life science partnering deal news, insights and glossary

Print Friendly, PDF & Email